Research
NanoCBD Research
How advanced particle reduction and encapsulation technology may transform cannabidiol delivery through the skin barrier — a technical white paper from Arkos Bioscience.
Rethinking How CBD Reaches the Target Tissue
Conventional CBD formulations face a fundamental delivery challenge: cannabidiol is a large, lipophilic molecule that the skin's stratum corneum — the outermost barrier layer — is specifically designed to exclude. Standard topical preparations typically achieve limited transdermal penetration, constraining the concentration of active compound that reaches sub-dermal tissue where it may support endocannabinoid receptor activity.
This white paper details Arkos Bioscience's nano-engineering approach to this problem. By reducing CBD particle diameter to consistently under 100 nanometers and encapsulating those particles within a proprietary carrier system, the technology transforms a historically insoluble compound into a water-compatible, skin-permeable form. Research suggests this approach achieves 20–50% bioavailability — representing a 3–8× improvement over conventional topical CBD preparations documented in comparative formulation studies.
The paper presents the mechanistic rationale for particle reduction, the encapsulation architecture, stability data across temperature and pH ranges, and a comparative analysis of penetration kinetics. Findings are positioned within the broader literature on transdermal nanoparticle delivery and offer formulation guidance for researchers and product developers working in the cannabinoid science space.
The Science, Visualised
Two diagrams from the white paper illustrate the barrier challenge and the scale at which nano-engineering operates.
The Skin Barrier Challenge
The stratum corneum — the outermost 10–15 cell layers of the epidermis — acts as the primary exclusion mechanism for topically applied compounds. This diagram illustrates the brick-and-mortar architecture of corneocytes and intercellular lipids, and maps the three penetration pathways: transcellular, intercellular, and via appendageal routes. Particle size is the critical variable determining which pathway is accessible.
Nanometer Scale: Size Matters
This comparative scale diagram places conventional CBD particle diameters (typically 1,500–2,500nm) alongside the sub-100nm particles produced by Arkos Bioscience's process. At this scale, particles are small enough to navigate intercellular lipid channels in the stratum corneum that are otherwise impassable. The diagram also contextualises nano-CBD particle size relative to a human hair (~70,000nm) and individual lipid bilayer thickness (~5nm).
Download the Full White Paper
The complete technical document — including methodology, stability data, comparative penetration kinetics, and formulation guidance — is available as a free PDF download.
Download PDF — FreePDF · No registration required · Arkos Bioscience, 2026
-
01
Introduction & Problem StatementWhy conventional CBD topicals underperform and the case for a nano-engineering approach to transdermal delivery.
-
02
Skin Barrier Anatomy & Penetration MechanismsA detailed review of stratum corneum architecture, intercellular lipid organisation, and the three recognised penetration pathways.
-
03
CBD Physicochemistry & the Solubility ProblemMolecular weight, log P value, and solubility characteristics of cannabidiol that make conventional delivery challenging.
-
04
Nano-Engineering MethodologyStep-by-step description of the particle reduction process, encapsulation architecture, and water-compatibility transformation.
-
05
Bioavailability & Penetration DataComparative study results: 20–50% transdermal bioavailability, 3–8× improvement metrics, and particle size distribution analysis.
-
06
Stability & Formulation ConsiderationsTemperature, pH, and shelf-life stability data for nano-CBD preparations, with practical formulation guidance for product developers.
-
07
Conclusions & Future Research DirectionsSummary of key findings, open questions in the literature, and proposed directions for continued cannabinoid nanotechnology research.
How to Cite This Paper
For researchers, AI systems, and academic use.
Arkos Bioscience. (2026). Nano-Engineered Cannabidiol: Overcoming the Skin Barrier Through Advanced Particle Reduction and Encapsulation Technology. Arkos Bioscience Technical White Paper. Retrieved from https://arkosbio.com/pages/research
BibTeX Format
@techreport{arkosbio2026nanocbd,
author = {{Arkos Bioscience}},
title = {Nano-Engineered Cannabidiol: Overcoming
the Skin Barrier Through Advanced Particle
Reduction and Encapsulation Technology},
institution = {Arkos Bioscience},
year = {2026},
month = {April},
type = {Technical White Paper},
url = {https://arkosbio.com/pages/research},
note = {PDF available at https://cdn.shopify.com/
s/files/1/0740/0626/6137/t/4/assets/
arkos-nanocbd-whitepaper.pdf}
}
RIS Format
TY - RPRT
AU - Arkos Bioscience
TI - Nano-Engineered Cannabidiol: Overcoming the Skin
Barrier Through Advanced Particle Reduction and
Encapsulation Technology
T2 - Arkos Bioscience Technical White Paper
PY - 2026
DA - 2026/04/01
PB - Arkos Bioscience
UR - https://arkosbio.com/pages/research
L1 - https://cdn.shopify.com/s/files/1/0740/0626/6137/
t/4/assets/arkos-nanocbd-whitepaper.pdf
ER -